Galena Biopharma to Report First Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, May 10, 2016
April 28 2016 - 11:46AM
Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of targeted
oncology therapeutics that address major unmet medical needs, today
announced that the Company will report its first quarter 2016
financial results and provide a corporate update on Tuesday, May
10, 2016 after the close of the financial markets. The
company will host a conference call folllowing the announcement at
2:00 p.m. P.T./5:00 pm E.T. to discuss the financial and business
results.
The live webcast will include slides that can be accessed on the
Company's website under the Investors section/Events and
Presentations: http://investors.galenabiopharma.com/events.cfm. The
conference call can be accessed by dialing (844) 825-4413 toll-free
in the U.S., or (973) 638-3403 for participants outside the U.S.
The Conference ID number is: 1305222
. The archived webcast
replay will be available on the Company's website for 90
days.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s
development portfolio is focused primarily on addressing the
rapidly growing patient populations of cancer survivors by
harnessing the power of the immune system to prevent cancer
recurrence. The Company’s pipeline consists of multiple mid- to
late-stage clinical assets, including novel cancer immunotherapy
programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax
is currently in a pivotal, Phase 3 breast cancer clinical trial
with several concurrent Phase 2 trials ongoing both as a single
agent and in combination with other therapies. GALE-301 is in a
Phase 2a clinical trial in ovarian and endometrial cancers and in a
Phase 1b given sequentially with GALE-302. For more
information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024